Verastem, Inc. to Present on Focal Adhesion Kinase Program at the 11th International Conference of the International Mesothelioma Interest Group

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verastem, Inc., (NASDAQ: VSTM) a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells, announced the presentation of data at the International Conference of the International Mesothelioma Interest Group being held September 11 – 15, 2012, in Boston, MA.
MORE ON THIS TOPIC